WASHINGTON, United States (AFP) — Moderna said Thursday that protection from its Covid-19 vaccine remained strong for at least six months, and the variant-specific boosters shot it is testing generated a “robust” antibody response to Delta. In a final analysis from its Phase 3, or final stage, clinical trial, Moderna’s Covid vaccine showed 93 percent efficacy at six months following the second dose. The company is also carrying out clinical trials on three different Covid-19 […]